Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Launched by AMGEN · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • Diagnosis of AIDS and persistent Mycobacterium avium- intracellulare (MAI) bacillemia.
• • Life expectancy of at least 3 months.
• • Baseline chest X-ray and EKG (electrocardiogram).
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Known hypersensitivity to interferons or other exogenous lymphokine.
• • History of cardiac abnormality or disease.
• • History of hypertension.
• Patients with the following are excluded:
• • Known hypersensitivity to interferons or other exogenous lymphokine.
• • History of cardiac abnormality or disease.
• • History of hypertension.
• Prior Medication:
• Excluded within 4 weeks of study entry:
• • Corticosteroids.
• • Anti-inflammatory medication (except aspirin).
• • Changes in the dose of anti-mycobacterial drugs.
• • Immune agents.
• Prior Treatment:
• Excluded within 4 weeks of study entry:
• • Radiotherapy.
• Risk Behavior:
• Excluded:
• • Intravenous drug abuse.